Century Therapeutics Inc is a biotechnology business based in the US. Century Therapeutics shares (IPSC) are listed on the NASDAQ and all prices are listed in US Dollars. Century Therapeutics employs 170 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $8.79 |
|---|---|
| 52-week range | $7.32 - $32.90 |
| 50-day moving average | $9.32 |
| 200-day moving average | $14.50 |
| Wall St. target price | $25.20 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.57 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.79 from 2022-07-01
| 1 week (2022-06-24) | -3.19% |
|---|---|
| 1 month (2022-06-03) | 9.33% |
| 3 months (2022-04-04) | -28.77% |
| 6 months (2022-01-04) | -42.25% |
| 1 year (2021-07-02) | -69.96% |
|---|---|
| 2 years (2020-06-30) | N/A |
| 3 years (2019-06-30) | N/A |
| 5 years (2017-06-30) | N/A |
| Revenue TTM | $1.1 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -15.58% |
| Return on equity TTM | -36.25% |
| Profit margin | 0% |
| Book value | $6.72 |
| Market capitalisation | $517.3 million |
TTM: trailing 12 months
We're not expecting Century Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Century Therapeutics, Inc. , a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.